The latest news and updates
JUL 2, 2024

SOURCE: Genetic Engineering News

Enzymatic DNA Synthesis: Shorter Waits, Longer Strands

Genetic Engineering News reviews several DNA manufacturing technologies that have emerged to give synthetic biology companies what they need to revolutionize the life sciences

JUN 10, 2024

SOURCE: BizTech Outlook

Elegen Named Among Top 10 Innovative Companies 2024

BizTech Outlook named Elegen among the Top Innovative Companies to Watch in 2024. Read this interview to learn why innovation is this company’s DNA.

MAY 14, 2024

SOURCE: Elegen News

Elegen Raises $35 Million in Series B to Accelerate Expansion into Clinical Manufacturing

Elegen announced a Series B financing of $35 million led by Triatomic Capital. Also joining the round are strategic investors GSK, which recently entered a collaboration and licensing agreement with Elegen to use their proprietary cell-free DNA manufacturing technology in developing GSK’s vaccines and medicines; John Ballantyne, co-founder of Aldevron; and existing investors.

APR 29, 2024


Elegen’s High-Complexity DNA Synthesis Accelerates the Development of Designer Polyketide Molecules

The Keatinge-Clay lab at the University of Texas at Austin ordered de novo synthesis of a 14,713 bp plasmid containing a PKS gene cluster. Elegen’s rapid, full-length plasmid synthesis saved the lab weeks of assembly time and labor when compared to traditional approaches. With Elegen’s ability to synthesize regions of high complexity, labs are able to move projects with difficult, complex sequences, including repetitive GC-rich regions, from the drawing board to the incubators in a matter of weeks.

APR 22, 2024


Elegen’s Cell-Free DNA Synthesis Speeds the Discovery and Development of Genetic Medicines

Marc Unger, Chief Scientific Officer, talks about Elegen’s cell-free DNA synthesis technology ENFINIA™ DNA, how it changes the paradigm of discovery and development for genetic medicines, and the company’s recent collaboration with GSK.

APR 15, 2024


Big4Bio Podcast: Solving Major Bottlenecks in Genetic Medicine & SynBio w DNA Synthesis Innovation

In this episode of Big4Bio’s Company to Watch, Danny Levine interviews Matthew Hill, Ph.D., founder and CEO of Elegen, on the next big innovation in manufacturing DNA, which bypasses synthetic DNA bottlenecks to accelerate upstream and downstream workflows.

APR 08, 2024


Removing Bottlenecks in Synthetic Biology with Cell-Free Synthesis of Long and Complex DNA

Randy Dyer, Vice President of Marketing, discusses the mission to unlock the promise of synthetic biology by eliminating a critical bottleneck in the supply of synthetic DNA for genetic medicine development and other biotechnology applications.

MAR 20, 2024

SOURCE: Elegen News

Elegen Launches ENFINIA™ DNA Enhancement for Rapid Synthesis of Highly Complex DNA

Following successful, fully subscribed Early Access and Beta Programs, Elegen’s latest ENFINIA DNA enhancement provides access to very challenging sequences, including long repeats and STRs, GC-rich promoters, enhancers, terminators, ITRs, LTRs and homopolymers.

MAR 19, 2024

SOURCE: Fast Company

The World's Most Innovative Companies of 2024

Elegen has been named among the world’s most innovative companies by Fast Co., ranked #2 in Small but Mighty.

MAR 06, 2024

SOURCE: The Healthcare Technology Report

The Top 25 Biotechnology Companies of 2024

Elegen has been named among the Top 25 Biotechnology Companies of 2024 by the Healthcare Technology Report.

FEB 01, 2024

SOURCE: BioCompare

Improving Cell and Gene Therapy Process Development

Cell and gene therapies (CGT) represent the cutting edge of biotherapeutics, using DNA and life itself as therapeutic agents. CGT process development requires the coordination of many parts, including cells, DNA constructs, and gene delivery vectors. As a key starting material, CGT development requires a constant flow of high-accuracy, long, and complex custom DNA. Elegen is addressing this synthesis bottleneck with its cell-free DNA synthesis process.

JAN 31, 2024

SOURCE: SynBioBeta

Health and Medicine News: Elegen Partners with GSK

Exclusive Interview: Elegen CEO Matthew Hill on new collaboration with GSK.

JAN 27, 2024

SOURCE: Life Science Success Podcast

Life Science Success Podcast: Cell-free DNA Synthesis of Industry Leading Long and Complex DNA

In this episode of Life Science Success Don Davis interviews guest Matt Hill, founder and CEO of Elegen, a privately-held company based in the San Francisco Bay Area, committed to revolutionizing synthetic biology workflows with an innovative DNA writing technology.

JAN 24, 2024

SOURCE: Genetic Engineering News

GSK and Elegen Team Up to Develop DNA-Based Medicines and Vaccines

Elegen’s ability to produce NGS-verified linear DNA up to 7 kb within a week with error rates as low as 1:70,000 per bp (99.999% per base accuracy) could be an important marker as it tries to establish a leading position in a heated race to deliver what could be the next major medicinal breakthrough.

JAN 24, 2024

SOURCE: Elegen News

Elegen Announces Multi-Year Collaboration and Licensing Agreement with GSK

GSK has signed a collaboration & licensing agreement to leverage Elegen’s cell-free DNA manufacturing technology in the development of GSK’s vaccines & medicines.

JAN 10, 2024

SOURCE: Business Intelligence Group

11 Executives, 47 Companies and 108 Products Win 2024 BIG Innovation Award

Business Intelligence Group Announces the Winners of the 2024 BIG Innovation Awards

DEC 04, 2023

SOURCE: Technology Networks

Synthetic DNA Advances Will Catalyze the Next Wave of Biotherapeutic Innovation

Recent innovations in DNA manufacturing are helping eliminate critical bottlenecks to bring new therapies to market faster than ever.

OCT 31, 2023

SOURCE: Nature Biotechnology

DNA Writing Technologies Moving Towards Synthetic Genomes

Nature reviews the latest advancements in DNA synthesis and the key challenges the new players like Elegen are quickly overcoming.

OCT 03, 2023

SOURCE: Biocompare

Cell Expansion for Cell Therapies

Biocompare recently published on the challenges of scaling cell therapies. Part of this challenge starts UPSTREAM in determining the optimal DNA sequence for expansion–a time-consuming, resource-intensive process.

JUL 01, 2023

SOURCE: Drug Discovery World Magazine

Accelerating Biotherapy and Personalized Medicine with Long DNA

Matt Hill, Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development.

JUN 14, 2023

SOURCE: BIOS Community

BIOS Builders Episode 15

Podcast featuring Matt Hill – Founder & CEO of Elegen

MAY 23, 2023

SOURCE: Elegen News

Elegen Early Access Partners Receive High-Complexity, Long DNA Sequences in Rapid Time

DNA lengths of 15,000 base pairs and higher represent twice the length of the Company’s recently launched flagship product, ENFINIA DNA, and industry-leading complexity and turnaround time

MAY 16, 2023

SOURCE: Elegen News

Elegen Launches New Online Ordering Portal for Rapid, High-Accuracy, Long DNA

Company focuses on ease of use, utility, and speed to increase ENFINIA DNA’s impact on workflow efficiency and productivity.

APR 24, 2023

SOURCE: Forbes

Synthetic Biology Is Set To Explode, But Only Once This Huge Bottleneck Is Gone

Guest author John Cumbers, CEO of SynBioBeta meets with Elegen Founder and CEO, Matthew Hill

APR 20, 2023

SOURCE: Mendelspod

Elegen Pioneers Long DNA Subindustry with CEO, Matt Hill

Mendelspod Podcast Featuring Elegen CEO and Founder, Matthew Hill

APR 12, 2023

SOURCE: GenomeWeb

Synthetic DNA Startup Elegen Gains Traction With Customers, Funders

Note: GenomeWeb Premium Subscription Required

MAR 21, 2023

SOURCE: Elegen News

Elegen Launches ENFINIA DNA

New product delivers up to 7kb of high-accuracy DNA in as fast as 7 days, providing an unparalleled combination of speed, length, and quality to the synthetic biology market

FEB 09, 2023

SOURCE: Genetic Engineering News

Enabling the Synthetic Biology Revolution

The team at Elegen knows that when barriers to the fast, accurate, and low-cost synthesis of long DNA fall, biotechnology will be driven by the design-build-test-learn cycle